Exhibit 99.1
Contacts:
John McLaughlin |
| Jennifer Williams | |||
PDL BioPharma, Inc. |
| Cook Williams Communications | ||
775-832-8500 |
| 360-668-3701 | |||
john.mclaughlin@pdl.com |
| jennifer@cwcomm.org | ||
PDL BioPharma Announces Fourth Quarter and Full Year 2012 Financial Results
INCLINE VILLAGE, NV, March 1, 2013 –PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today reported financial results for the fourth quarter and full year ended December 31, 2012.
Total revenues in 2012 were $374.5 million, compared to $362.0 million in 2011, with royalty revenues increasing seven percent over full year 2011. For the fourth quarter of 2012, total revenues were $86.0 million, compared to $72.8 million in the fourth quarter of 2011.
Royalty revenues for the fourth quarter of 2012 are based on third quarter product sales by PDL’s licensees. The fourth quarter 2012 revenue growth was primarily driven by increased royalties from third quarter 2012 sales of Herceptin® and Avastin®, which are marketed by Genentech and Roche. Royalty revenue for the fourth quarter and 2012 are net of payments made under our February 2011 settlement agreement with Novartis Pharma AG.
Operating expenses in 2012 were $25.5 million, compared with $18.3 million in 2011. For the fourth quarter of 2012, general and administrative expenses were $7.7 million compared with $4.8 million for the same period of 2011.
Net income in 2012 was $211.7 million, or $1.45 per diluted share as compared with net income of $199.4 million in 2011 or $1.15 per diluted share. Net income for the fourth quarter of 2012 was $49.4 million or $0.34 per diluted share as compared with net income of $38.9 million or $0.24 per diluted share for the same period of 2011.
Net cash provided by operating activities in 2012 was $210.2 million, compared with $169.8 million in 2011. At December 31, 2012, PDL had cash, cash equivalents and investments of $148.7 million, compared with $227.9 million at December 31, 2011. The reduction in cash relates primarily to the Company’s income generating asset transactions, repayment of the Company’s non-recourse notes and dividend payments.
Recent Developments
Kadcyla™ or T-DM1, a New Royalty-Bearing Product of PDL
On February 22, 2013, Genentech announced that the U.S. Food and Drug Administration (FDA) approved Trastuzumab emstansine (T-DM1), now named Kadcyla. Kadcyla was approved for second line treatment of HER2+ metastatic breast cancer and first line treatment for those patients who relapse within six months following adjuvant therapy. Roche has submitted a Marketing Authorization Application to the European Medicines Agency (EMA) for the same indication. Kadcyla is a licensed product of Genentech and has been priced at $9800 per month. PDL expects to receive royalties on sales of Kadcyla in the quarter following the first quarter of sales in accordance with Genentech's license agreements with PDL.
Avastin, a Royalty-Bearing Product of PDL
In October, Genentech and Roche announced that the European Commission approved Avastin in combination with standard chemotherapy (carboplatin and gemcitabine) as a treatment for women with first recurrence of platinum-sensitive ovarian cancer. In November, the European Medicines Agency adopted a positive opinion regarding the use of Avastin in second-line metastatic colorectal cancer. Also in November, additional details were announced regarding Phase 3 patients with newly diagnosed glioblastoma, who were treated with Avastin plus radiation and chemotherapy, which showed an increase in progression-free survival of 36 percent when compared to radiation and chemotherapy.
Obinutuzumab, a Potential Royalty-Bearing Product of PDL
In January, Genentech announced Phase 3 results from an obinutuzumab (GA101) trial showing a significant improvement in progression-free survival in people with chronic lymphocytic leukemia (CLL). Data from this trial will be submitted to European regulatory authorities and to the U.S. Food and Drug Administration (FDA) for potential approval.
2013 Dividends
On January 30, 2013, PDL’s Board of Directors declared regular quarterly dividends of $0.15 per share of common stock, payable on March 12, June 12, September 12 and December 12 of 2013 to all stockholders who own shares of PDL on March 5, June 5, September 5 and December 5 of 2013, the record dates for each of the dividend payments, respectively.
Revenue Guidance for 2013
As previously announced, PDL will continue to provide revenue guidance for each quarter in the third month of that quarter. First quarter 2013 revenue guidance will be provided in early March.
Conference Call Details
PDL will hold a conference call to discuss financial results at 4:30 p.m. ET today, March 1, 2013.
To access the live conference call via phone, please dial (800) 668-4132 from the United States and Canada or (224) 357-2196 internationally. Please dial in approximately 10 minutes prior to the start of the call. A telephone replay will be available beginning approximately one hour after the call through March 8, 2013, and may be accessed by dialing (855) 859-2056 from the United States and Canada or (404) 537-3406 internationally. The replay passcode is 12523654.
To access the live and subsequently archived webcast of the conference call, go to the Company’s website athttp://www.pdl.com and go to “Company Presentations & Events.” Please connect to the website at least 15 minutes prior to the call to allow for any software download that may be necessary.
About PDL BioPharma
PDL pioneered the humanization of monoclonal antibodies and, by doing so, enabled the discovery of a new generation of targeted treatments for cancer and immunologic diseases. Today, PDL is focused on intellectual property asset management, investing in new income generating assets and maximizing value for its shareholders. For more information, please visit www.pdl.com.
NOTE: PDL BioPharma and the PDL BioPharma logo are considered trademarks of PDL BioPharma, Inc.
Forward-looking Statements
This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Each of these forward-looking statements involves risks and uncertainties. Actual results may differ materially from those, express or implied, in these forward-looking statements. Important factors that could impair the value of the Company's royalty assets, restrict or impede the ability of the Company to invest in new income generating assets and limit the Company's ability to pay dividends are disclosed in the risk factors contained in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission. All forward-looking statements are expressly qualified in their entirety by such factors. We do not undertake any duty to update any forward-looking statement except as required by law.
PDL BIOPHARMA, INC.
CONDENSED CONSOLIDATED STATEMENTS OF INCOME DATA
(Unaudited)
(In thousands, except per share amounts)
Three Months Ended | Year Ended | |||||||||||||||
December 31, | December 31, | |||||||||||||||
2012 | 2011 | 2012 | 2011 | |||||||||||||
Revenues | ||||||||||||||||
Royalties | $ | 86,046 | $ | 72,808 | $ | 374,525 | $ | 351,641 | ||||||||
License and other | - | - | - | 10,400 | ||||||||||||
Total revenues | 86,046 | 72,808 | 374,525 | 362,041 | ||||||||||||
Operating Expenses | ||||||||||||||||
General and administrative expenses | 7,732 | 4,822 | 25,469 | 18,338 | ||||||||||||
Operating income | 78,314 | 67,986 | 349,056 | 343,703 | ||||||||||||
Non-operating expense, net | ||||||||||||||||
Loss on retirement or conversion of convertible notes | - | - | - | (766 | ) | |||||||||||
Interest and other income, net | 4,728 | 130 | 7,113 | 593 | ||||||||||||
Interest expense | (5,950 | ) | (8,161 | ) | (29,036 | ) | (36,102 | ) | ||||||||
Total non-operating expense, net | (1,222 | ) | (8,031 | ) | (21,923 | ) | (36,275 | ) | ||||||||
Income before income taxes | 77,092 | 59,955 | 327,133 | 307,428 | ||||||||||||
Income tax expense | 27,684 | 21,013 | 115,464 | 108,039 | ||||||||||||
Net income | $ | 49,408 | $ | 38,942 | $ | 211,669 | $ | 199,389 | ||||||||
Net income per share | ||||||||||||||||
Basic | $ | 0.35 | $ | 0.28 | $ | 1.52 | $ | 1.43 | ||||||||
Diluted | $ | 0.34 | $ | 0.24 | $ | 1.45 | $ | 1.15 | ||||||||
Shares used to compute income per basic share | 139,764 | 139,680 | 139,711 | 139,663 | ||||||||||||
Shares used to compute income per diluted share | 145,419 | 167,683 | 146,403 | 177,441 | ||||||||||||
Cash dividends declared per common share | $ | - | $ | - | $ | 0.60 | $ | 0.60 | ||||||||
PDL BIOPHARMA, INC.
CONDENSED CONSOLIDATED BALANCE SHEET DATA
(Unaudited)
(In thousands)
December 31, | ||||||||
2012 | 2011 | |||||||
Cash, cash equivalents and investments | $ | 148,689 | $ | 227,946 | ||||
Total assets | $ | 279,966 | $ | 269,471 | ||||
Convertible notes payable | $ | 309,952 | $ | 316,615 | ||||
Non-recourse notes payable | $ | - | $ | 93,370 | ||||
Total stockholders' deficit | $ | (68,122 | ) | $ | (204,273 | ) | ||
PDL BIOPHARMA, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOW DATA
(Unaudited)
(In thousands)
Year Ended | ||||||||
December 31, | ||||||||
2012 | 2011 | |||||||
Net income | $ | 211,669 | $ | 199,389 | ||||
Adjustments to reconcile net income to net cash provided by operating activities | 26,644 | 43,574 | ||||||
Changes in assets and liabilities | (28,097 | ) | (73,181 | ) | ||||
Net cash provided by operating activities | $ | 210,216 | $ | 169,782 | ||||
PDL BIOPHARMA, INC.
MIX OF EX-U.S. SALES AND EX-U.S.-BASED MANUFACTURING AND SALESOF GENENTECH PRODUCTS
(Unaudited)
Three Months Ended | Year Ended | ||||||||||||||||
December 31, | December 31, | ||||||||||||||||
2012 | 2011 | 2012 | 2011 | ||||||||||||||
Avastin | |||||||||||||||||
% Ex-U.S. Sold | 57 | % | 53 | % | 56 | % | 55 | % | |||||||||
% Ex-U.S.-based Manufactured and Sold | 40 | % | 28 | % | 29 | % | 21 | % | |||||||||
Herceptin | |||||||||||||||||
% Ex-U.S. Sold | 69 | % | 68 | % | 69 | % | 71 | % | |||||||||
% Ex-U.S.-based Manufactured and Sold | 35 | % | 26 | % | 37 | % | 35 | % | |||||||||
Lucentis | |||||||||||||||||
% Ex-U.S. Sold | 66 | % | 60 | % | 63 | % | 59 | % | |||||||||
% Ex-U.S.-based Manufactured and Sold | 0 | % | 0 | % | 0 | % | 0 | % | |||||||||
Xolair | |||||||||||||||||
% Ex-U.S. Sold | 38 | % | 40 | % | 39 | % | 40 | % | |||||||||
% Ex-U.S.-based Manufactured and Sold | 38 | % | 40 | % | 39 | % | 40 | % | |||||||||